Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO)
Biomarker and diagnostic research for papillary craniopharyngioma has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
146 publications have been identified in PubMed for papillary craniopharyngioma. Research spans Review / Meta-Analysis (40%), Case Report / Case Series (16%), and Basic Science / Preclinical (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 54 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 5:33 AM UTC
Patient case studies | 21 | 16% |
Laboratory research | 19 | 14% |
Disease patterns and progression | 16 | 12% |
Clinical study results | 13 | 10% |
Other research | 6 | 4% |
Testing and diagnosis research | 4 | 3% |
New treatment approaches | 2 | 1% |
Müller HL (2026). [PMID: 41224353](https://pubmed.ncbi.nlm.nih.gov/41224353/). *Endocr J*. [Review / Meta-Analysis]
Zhang B (2026). [PMID: 41159376](https://pubmed.ncbi.nlm.nih.gov/41159376/). *Neuro-oncology*. [Clinical Trial Publication]
Juratli TA (2026). [PMID: 42224718](https://pubmed.ncbi.nlm.nih.gov/42224718/). *Neurosurg Focus*. [Review / Meta-Analysis]
Jones PS (2026). [PMID: 42224720](https://pubmed.ncbi.nlm.nih.gov/42224720/). *Neurosurg Focus*. [Review / Meta-Analysis]
Neubecker JJ (2026). [PMID: 41898146](https://pubmed.ncbi.nlm.nih.gov/41898146/). *Biomedicines*. [Review / Meta-Analysis]
Wang W (2026). [PMID: 42164118](https://pubmed.ncbi.nlm.nih.gov/42164118/). *Front Oncol*. [Diagnostic / Biomarker]
Cabezas-Camarero S (2026). [PMID: 42046771](https://pubmed.ncbi.nlm.nih.gov/42046771/). *Neurooncol Adv*. [Gene Therapy / Novel Therapeutics]
Fudaba H (2026). [PMID: 42083012](https://pubmed.ncbi.nlm.nih.gov/42083012/). *Acta Neuropathol Commun*. [Case Report / Case Series]
Zhao C (2026). [PMID: 41920205](https://pubmed.ncbi.nlm.nih.gov/41920205/). *Clin Exp Med*. [Basic Science / Preclinical]
Lotfian G (2026). [PMID: 40773058](https://pubmed.ncbi.nlm.nih.gov/40773058/). *Neuroradiology*. [Case Report / Case Series]
AI-curated news mentioning papillary craniopharyngioma
Updated May 11, 2026
The OUTSPREAD study investigates the effects of growth hormone treatment on linear growth and metabolic outcomes in patients with childhood-onset craniopharyngioma. Findings contribute to understanding treatment impacts in this rare disease population.